The Use of Dopamine Agonists and Antagonists in Neurology

  • Harold L. Klawans
  • Christopher G. Goetz
  • Caroline M. Tanner
Part of the New Horizons in Therapeutics book series (NHTH)


Both dopamine agonists and antagonists have been used to treat neurological disorders. In some instances, in fact, both classes of drugs have been used in the same disease states (e.g., chorea, dystonia, minimal brain dysfunction). Both agonists and antagonists have also been implicated in the pathogenesis of neurological dysfunction, including one disorder that can be induced by treatment with either class of agent (dyskinesias). A review of all neurological disorders in which dopamine systems may play a role is beyond the scope of this brief chapter, which focuses on two areas of particular interest to our research group: (1) dopamine agonists in the treatment of parkinsonism and (2) dopamine antagonists in the etiology of neuroleptic-induced tardive dyskinesias.


Dopamine Agonist Tardive Dyskinesia Stereotyped Behavior Ergot Alkaloid Dopamine Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Calne, D. B., 1978, Dopaminergic agonists in the treatment of parkinsonism, in: Clinical Neuropharmacology, Volume 3 (H. L. Klawans, ed.), Raven Press, New York, pp. 153–166.Google Scholar
  2. Calne, D. B., and Ward, C, 1981, Current concepts on the treatment of Parkinson’s disease-the use of dopamine agonists, in: 12th World Congress of Neurology, Kyoto, Japan, September 20-25, Excerpta Medica, Amsterdam, p. 134.Google Scholar
  3. Cotzias, G. C, Van Woert, M. H., and Schiffer, L. M., 1967, Aromatic amino acids and modification of parkinsonism, N. Engl. J. Med. 276:374–379.PubMedCrossRefGoogle Scholar
  4. Gianutsos, G., Drawbaugh, R. B., Hynes, M. D., and Lal, H., 1974, Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol, Life Sci. 14:887–898.PubMedCrossRefGoogle Scholar
  5. Glantz, R., Goetz, C. G., Nausieda, P. A., Weiner, W. J., and Klawans, H. L., 1981, The effect of bromocriptine (BCT) on the on-off phenomenon, J. Neural Transm. 52:41–47.PubMedCrossRefGoogle Scholar
  6. Goetz, C. G., Weiner, W. J., Nausieda, P. A., and Klawans, H. L., 1982, Tardive dyskinesia: Pharmacology and clinical implications, Clin. Neuropharmacol. 5:3–22.PubMedCrossRefGoogle Scholar
  7. Guldberg, H. C, and Yates, C. M., 1969, Effects of chlorpromazine on the metabolism of catecholamines in dog brain, Br. J. Pharmacol. 36:535–537.PubMedCrossRefGoogle Scholar
  8. Hitri, A., Carvey, P., Weiner, W. J., and Klawans, H. L., 1980, Biochemical and behavioral studies of neuroleptic induced behavioral supersensitivity, in: Tardive Dyskinesia (W. E. Fann, R. C. Smith, J. M. Davis, and E. F. Domino, eds.), S. P. Press, New York, pp. 145–163.CrossRefGoogle Scholar
  9. Ilson, J., Fahn, S., Mayeax, R., Cote, L. J., and Snider, S. R., 1983, pergolide in parkinsonism, Adv. Neurol. 37:85–94.PubMedGoogle Scholar
  10. Kartzinel, R., Perlow, M., Teychenne, P., Gielin, A. C, Gillespie, M. M., Sadowsky, D. A., and Calne, D. B., 1976a, Bromocriptine and levodopa (with or without carbidopa) in parkinsonism, Lancet 2:212–215.Google Scholar
  11. Kartzinel, R., Hunt, R. D., and Calne, D. B., 1976b, Bromocriptine in Huntington’s chorea, Arch. Neurol. 33:517–518.CrossRefGoogle Scholar
  12. Klawans, H. L., 1973, The Pharmacology of Extrapyramidal Movement Disorders, S. Karger, Basel.Google Scholar
  13. Klawans, H. L., and Rubovits, R., 1972, An experimental model of tardive dyskinesia, J. Neural Transm. 33:235–246.PubMedCrossRefGoogle Scholar
  14. Klawans, H. L., Goetz, C, Volkman, P., Nauseida, P. A., and Weiner, W. J., 1978, Lergotrile in the treatment of parkinsonism, Neurology (Minneap.) 28:699–702.CrossRefGoogle Scholar
  15. Klawans, H. L., Carvey, P., Nausieda, P. A., Goetz, C. G., and Weiner, W. J., 1980, Effect of dose and type of neuroleptic in an animal model of tardive dyskinesia, Neurology (N.Y.) 30:95.Google Scholar
  16. Klawans, H. L., Tanner, f C. M., Goetz, C. G., Glatt, S., Nausieda, P. A., and Weiner, W. J., 1981, Pergolide mesylate therapy in Parkinson disease: Report of a three month trial in 20 patients, Neurology (N.Y.) 31(Suppl.):133.Google Scholar
  17. Kleinberg, D. L., Lieberman, A., Todd, J., Greising, J., Neophytides, A., and Keyser-Smith, A., 1980, Pergolide mesylate: A potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson’s disease, J. Clin. Endocrinol. Metab. 51:152–154.PubMedCrossRefGoogle Scholar
  18. Lieberman, A., Miyamoto, T., Battista, A. F., and Goldstein, M., 1975, Studies on the antiparkinsonian efficacy of lergotrile, Neurology (Minneap.) 25:459–462.CrossRefGoogle Scholar
  19. Lieberman, A., Kupersmith, M., Estey, E., and Goldstein, M., 1976, Treatment of Parkinson’s disease with bromocriptine, N. Engl. J. Med. 295:1400–1404.PubMedCrossRefGoogle Scholar
  20. Lieberman, A., Goldstein, M., Leibowitz, M., Neophytides, A., Kupersmith, M., Pact, V., and Kleinberg, D., 1981, Treatment of advanced Parkinson disease with pergolide, Neurology (N.Y.) 31:675–682.CrossRefGoogle Scholar
  21. Loeb, C, Roccatagaliata, G., Albano, C, and Besio, G., 1979, Bromocriptine and dopaminergic function in Huntington disease. Neurology (Minneap.) 29:730–734.CrossRefGoogle Scholar
  22. Nyback, H., and Sedvall, G., 1968, Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine C-14 in brain, J. Pharmacol. Exp. Ther. 162:294–301.PubMedGoogle Scholar
  23. Parkes, J. D., Marsden, C D., Donaldson, I., Galea-Debono, A., Walters, J., Kennedy, G., and Asselman, P., 1976, Bromocriptine treatment in Parkinson’s disease, J. Neurol. Neurosurg. Psychiatry 39:184–193.PubMedCrossRefGoogle Scholar
  24. Parkes, J. D., Schachter, M., Quinn, N., Lang, A., and Horowski, R., 1981, Bromocriptine, lisuride and pergolide in the treatment of Parkinson’s disease, in: Abstracts, 12th World Congress of Neurology, Kyoto, Japan, September 20-25, Excerpta Medica, Amsterdam, p. 330.Google Scholar
  25. Rinne, U. K., 1981, Dopaminergic agonists in the treatment of Parkinson’s disease, in: Abstracts, 12th World Congress of Neurology, Kyoto, Japan, September 20-25, Excerpta Medica, Amsterdam, p. 133.Google Scholar
  26. Rubovits, R., Patel, B.C., and Klawans, H. L., 1973, Effect of prolonged chlorpromazine pretreatment on the threshold for amphetamine stereotypy: A model for tardive dyskinesias, Adv. Neurol. 1:671–679.Google Scholar
  27. Schwab, R. S., Amador, L. V., and Lettvin, J. Y., 1951, Apomorphine in Parkinson’s disease, Trans. Am. Neurol. Assoc. 76:251–253.Google Scholar
  28. Tanner, C. M., Chhablani, R., Goetz, C G., and Klawans, H. L., 1982, Pergolide mesylate: Lack of cardiac toxicity in six patients with known heart disease, Neurology (N.Y.) 32: A6Google Scholar
  29. Tarsy, D., and Baldessarini, R. J., 1973, Pharmacologically induced behavioral supersensitivity to apomorphine, Nature (New Biol.) 245:262.Google Scholar
  30. Tolosa, E. S., and Sparber, S. B., 1974, Apomorphine in Huntington’s Chorea: Clinical observations and theoretical considerations, Life Sci. 15:1371–1380.PubMedCrossRefGoogle Scholar
  31. Yahr, M. D., 1981, Treatment of Parkinson’s disease, in: Abstracts, 12th World Congress of Neurology, Kyoto, Japan, September 20-25, Excerpta Medica, Amsterdam, pp. 134–135.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Harold L. Klawans
    • 1
  • Christopher G. Goetz
    • 1
  • Caroline M. Tanner
    • 1
  1. 1.Department of Neurological SciencesRush-Presbyterian St. Lukes Medical CenterChicagoUSA

Personalised recommendations